What are the benefits or constraints to go to a corporate venture tool? Is it better to go with a pharma player that wants to be a limited partner in existing funds rather than corporate ventures? AS both have fundamentally different missions, what are the validating and limitation effects of working with a corporate VC? How to balance these two effects?
With more than 1,000 international actors from 35+ countries, such as big pharma, emerging and small biotech, diagnostic companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment rounds in Life Sciences.
Learn more
Organised by
INSTITUTIONAL PARTNERS:
"*" indicates required fields
Lille Grand Palais
1, Boulevard des Cités Unies
59777 Lille, FRANCE
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not over the phone.Please be extremely vigilant.
